Coronavirus: Medical Treatments

Department of Health and Social Care written question – answered on 11th February 2022.

Alert me about debates like this

Photo of Lord Mendelsohn Lord Mendelsohn Labour

To ask Her Majesty's Government how many (1) immunocompromised, or (2) immunosuppressed, people have received (a) antiviral, or (b) monoclonal, antibody treatments for COVID-19.

Photo of Lord Kamall Lord Kamall The Parliamentary Under-Secretary for Health and Social Care

Information on the number of doses administered to immunocompromised people is not available in the format requested. These individuals are a priority for treatments, alongside those with other clinical conditions as determined by an independent advisory group.

The neutralising monoclonal antibody Ronapreve has been available to treat patients with COVID-19 in England since September 2021. As of 6 February 2022, 86 patients have been treated through COVID Medicines Delivery Units (CMDUs). The deployment of the neutralising monoclonal antibody sotrovimab began on 20 December 2021. As of 6 February 2022, 7,246 patients have been treated through CMDUs. The deployment of the oral antiviral molnupiravir began on 16 December 2021. As of 6 February 2022, 5,787 patients have been treated through CMDUs.

As of 16 January 2022, 4,962 patients have been treated with Ronapreve in hospitals; 457 patients have been treated with sotrovimab in hospitals; and 49,966 patients have been treated with Remdesivir in all settings. As of 8 February 2022, 7,868 people have been enrolled on the PANORAMIC national study, with half the participants receiving molnupiravir treatment.

Does this answer the above question?

Yes1 person thinks so

No0 people think not

Would you like to ask a question like this yourself? Use our Freedom of Information site.